NCT04150640View on ClinicalTrials.gov

Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 13, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Esophageal AdenocarcinomaGastric Adenocarcinoma
Interventions
DRUG

Nal-IRI

chemotherapy drug

DRUG

Oxaliplatin

chemotherapy drug

DRUG

5-FU

chemotherapy drug

DRUG

Trastuzumab

immunotherapy

DRUG

Pembrolizumab

immunotherapy

DRUG

Nivolumab

immunotherapy

Trial Locations (1)

53792

RECRUITING

University of Wisconsin Carbone Cancer Center, Madison

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

University of Wisconsin, Madison

OTHER